• Eltanexor: Next-Gen XPO1 Inhibitor for Cancer Research Wo...

  2025-10-20

  Eltanexor (KPT-8602) redefines cancer research by offering a potent, orally bioavailable XPO1 inhibitor that excels in both hematological and solid tumor models. Explore advanced experimental workflows, troubleshooting strategies, and mechanistic insights that set Eltanexor apart as a transformative tool for targeting the nuclear export pathway in cancer.

• Pemetrexed: Advanced Antifolate Workflows in Cancer Research

  2025-10-19

  Pemetrexed’s multi-targeted antifolate mechanism unlocks precision in disrupting nucleotide biosynthesis, offering researchers a dynamic tool to probe tumor cell vulnerabilities. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights for deploying pemetrexed in non-small cell lung carcinoma and malignant mesothelioma models.

• Eltanexor: Advancing XPO1 Inhibitor Applications in Cance...

  2025-10-18

  Eltanexor (KPT-8602) is redefining cancer research with its potent, oral inhibition of XPO1—unlocking new strategies in both hematological and solid tumor studies. This article translates cutting-edge bench findings into actionable protocols, highlights comparative advantages over earlier nuclear export inhibitors, and delivers troubleshooting tips for optimizing experimental outcomes.

93 records 7/7 page Previous First page 上5页 67